StreetInsider.com News Articles

Form 8-K BioXcel Therapeutics, For: Mar 10

Wed, 11 Mar 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260311/26146593.html

Form 8-K BioXcel Therapeutics, For: Mar 10

Wed, 11 Mar 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260311/26146593.html

BioXcel Therapeutics closes $8 million registered direct offering

Wed, 11 Mar 2026 16:20:09 -0400

BioXcel Therapeutics Inc. (NASDAQ: BTAI) completed a registered direct offering that raised approximately $8.0 million in gross proceeds before fees and expenses, the biopharmaceutical company announced.

The offering involved 4,500,785 shares of common stock and accompanying warrants at a combined price of $1.739 per share. The warrants allow holders to purchase up to 4,500,785 additional shares at $1.614 per share and expire five years from the issuance date.

The company also modified existing warrants held by the investor, reducing the exercise price to $1.614 per share for warrants covering 1,385,083 shares and extending their expiration dates to five years from the offering's

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Wed, 11 Mar 2026 16:20:00 -0400

NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,500,785 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant.

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Wed, 11 Mar 2026 16:20:00 -0400

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Wed, 11 Mar 2026 16:20:00 -0400

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Wed, 11 Mar 2026 16:20:00 -0400

Form 424B5 BioXcel Therapeutics,

Wed, 11 Mar 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20260311/26142984.html

Form 424B5 BioXcel Therapeutics,

Wed, 11 Mar 2026 08:09:00 -0400

si-local-file:///var/storage/secattach/20260311/26142984.html

BioXcel Therapeutics raises $8 million in registered direct offering

Tue, 10 Mar 2026 14:36:10 -0400

BioXcel Therapeutics Inc. (NASDAQ: BTAI) entered into a securities purchase agreement with an institutional investor for a registered direct offering of 4,500,785 shares of common stock and accompanying warrants to purchase an additional 4,500,785 shares.

The combined offering price is $1.739 per share and warrant. The warrants carry an exercise price of $1.614 per share, are exercisable immediately upon issuance, and expire five years from the issuance date.

The company also agreed to reduce the exercise price of existing warrants for 1,385,083 shares held by the same investor to $1.614 per share and extend their expiration dates to five years from the

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Tue, 10 Mar 2026 14:36:00 -0400

NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,500,785 shares of Common Stock at a combined offering price of

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Tue, 10 Mar 2026 14:36:00 -0400

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Tue, 10 Mar 2026 14:36:00 -0400

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Tue, 10 Mar 2026 14:36:00 -0400

BioXcel reports positive phase 2 results for BXCL501 in opioid withdrawal

Thu, 05 Mar 2026 07:00:33 -0400

BioXcel Therapeutics Inc. (NASDAQ: BTAI) announced positive results from a Phase 2 study evaluating BXCL501 for treating opioid withdrawal symptoms in adults with opioid use disorder undergoing methadone taper.

The Columbia University-led study, funded by the National Institute on Drug Abuse, enrolled 80 patients and compared BXCL501 at two dose levels against placebo and lofexidine, an approved opioid withdrawal treatment. The trial included participants predominantly exposed to fentanyl, with many exposed to fentanyl adulterated with xylazine.

BXCL501 at 240 micrograms twice daily reduced opioid withdrawal symptoms compared to placebo during a seven-day methadone taper, as measured by the Short Opiate Withdrawal Scale-Gossop.

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

Thu, 05 Mar 2026 07:00:00 -0400

BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms

Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal

BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms

Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal

BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms

Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal

BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms

Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal

Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia

Large patient population affected by Alzheimer’s agitation, with approximately ~100 million annual episodes1